Visual analysis based on CiteSpace software: a bibliometric study of atrial myxoma

Objective: To use CiteSpace and VOSviewer visual metrology to analyze the research status, frontier hotspots, and trends in research on atrial myxoma.

Methods: The Web of Science core collection database was used to retrieve relevant literature on atrial myxoma from 2001 to 2022. CiteSpace software was used to analyze keywords with a co-occurrence network, co-polymerization class, and burst terms, and a corresponding visual atlas was drawn for analysis.

Results: A total of 893 valid articles were included. The country with the highest number of articles was the United States (n = 186). The organization with the highest number of articles was the Mayo Clinic (n = 15). The author with the highest number of articles was Yuan SM (n = 12). The highest cited author was Reynen K (n = 312). The highest cited journal was Annals of Thoracic Surgery (n = 1,067). The most frequently cited literature was published in the New England Journal of Medicine in 1995, which was cited 233 times. The keywords co-occurrence, copolymerization analysis, and Burst analysis revealed that the main research focuses were surgical methods, case reports, and genetic and molecular level studies on the pathogenesis of myxoma.

Conclusions: This bibliometric analysis revealed that the main research topics and hotspots in atrial myxoma included surgical methods, case reports, genetic and molecular studies.

1. Introduction

In 2015, the International Agency for Research on Cancer (IARC) released the 4th edition of the “WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart” (1), which divided cardiac tumors into benign tumors, tumors of uncertain biologic behavior, germ cell tumors, and malignant tumors. Benign tumors mainly include myxoma, papillary fibroelastoma, and rhabdomyoma. Lipoma (2) and paraganglioma (3) are the rare types of cardiac benign tumor. Cardiac myxoma is the most common tumor of the heart, with an estimated annual incidence of 0.5 per million population (4). Left atrial myxoma is the most common cardiac myxoma, with an incidence of 75%–85% (5, 6). It usually happens to middle-aged people, but it can happen to people of any age. Furthermore, cardiac myxoma usually occurs in women, with a male to female ratio of 1:3 (7, 8).

The tissue origin of atrial myxoma has not been fully defined. At present, it is hypothesized to originate from subendocardial multipotent mesenchymal stem cells near the oval fossa (9). In addition, the pathogenesis of atrial myxoma remains unclear. Ninety percent of atrial myxoma patients rarely relapse after surgical resection. However, certain types of atrial myxoma have a high postoperative recurrence rate, such as the familial cluster onset of Carney syndrome myxoma (10). At present, surgical resection of tumor mass is the best treatment, and there is no effective drug treatment to curb the growth of tumor (11). The current surgical methods used to treat atrial myxoma fall into the following four categories: (1) resection of atrial myxoma by median thoracotomy (12); (2) small incision resection of atrial myxoma (13); (3) thoracoscopic-assisted resection of atrial myxoma (14); and (4) complete endoscopic resection of atrial myxoma (including total thoracoscopic cardiac surgery and robotic cardiac surgery) (15, 16). With rapid developments in the understanding of myxoma at the genetic and molecular level, new targeted drugs may be developed (17, 18); however, some controversy remains. Therefore, it is meaningful to gain knowledge on the development of cardiac myxoma. In this regard, we performed a statistical research analysis of the current literature on cardiac myxoma.

This study aimed to analyze the literature associated with atrial myxoma over 20 years to provide valuable insights into atrial myxoma. We applied CiteSpace and VOSviewer to visually analyze the related literature on atrial myxoma, and discussed its research status and cutting-edge hot research topics, with a view to providing a reference for follow-up research on the development of atrial myxoma.

2. Methods

2.1. Ethics statement

The present study did not involve any human subjects, and was entirely performed using bibliometric data retrieved from the Web of Science database (WOS, https://www.webofscience.com/wos/woscc/basic-search). Therefore, it is deemed exempt from Institutional Review Board approval.

2.2. Data sources and collection

Compared with other databases, Web of Science provides a comprehensive and standardized data set for reference, and has been widely used for bibliometric analysis (19).

The time span was set between January 01, 2001, and October 01, 2022. First, the “WOS Core Collection” was selected on the search page. The search was refined to the subject heading “Atrial Myxoma” and article types “Article” and “Review”. “Plain Text” was chosen for the file format, while “Full Record and Cited References” was chosen for the record content.

The search query string was described as follows: Atrial Myxoma (Topic) and Article or Review Article (Document Types).

2.3. Data analysis

The data were downloaded and analyzed by two researchers to assure the accuracy of data and the repeatability of the research. Microsoft Excel 2019 and GraphPad Prism 7 were applied to analyze the targeted files and to export the line charts and tables of the top-cited or productive countries/regions, institutions, authors, journals, references, and keywords.

The 2021 version of the impact factor and journal impact factor quartile, as important indicators to measure the scientific value of research, were also included in the analysis.

2.4. Bibliometric analysis and visualization software

CiteSpace (https://citespace.podia.com/download, R6.1.3), a freely available Java-based application, was designed to analyze and visualize trends and patterns in scientific literature, presenting the structure and distribution of scientific knowledge. It focuses on finding critical points in the development of a field or a domain, especially intellectual turning points and pivotal points (20). In this study, CiteSpace was used for keyword clustering and to highlight the results.

VOSviewer (https://www.vosviewer.com/, R1.6.18) is a bibliometric analysis software for mapping knowledge. It can be used for co-word analysis, co-citation analysis, coupling analysis of documents, and to visualize the results (21). In this study, VOSviewer was used to visualize countries, authors, institutional collaborations, cited journals, keyword co-occurrences, and to construct density maps.

3. Results

3.1. Analysis of global publishing trends

A total of 1,430 relevant documents were retrieved; 537 were excluded due to being conference summaries, letters, news, etc., and 893 valid documents were finally included. Since the establishment of the database, there are few early studies in this field. From 2001 to 2003, no original articles or reviews matching the search term “Atrial Myxoma” were included. From 2004 to 2021, the average annual number of papers reported each year was 48, with the highest number in 2012 being 66. Although atrial myxoma is an uncommon disease in the field of cardiology, certain scholars have studied it every year in recent decades, with a steady trend increase over time; however, after 2019, the number of documents issued declined, which may be related to the COVID-19 pandemic (Figure 1).

FIGURE 1

Figure 1. Annual trends of global publications.

3.2. Analysis of distribution and co-operation of leading countries/regions

A total of 48 countries/regions have published papers on atrial myxoma. The United States of America (USA) had the highest number of publications (n = 186, 20.83%), followed by China (n = 136, 15.23%), Turkey (n = 80, 8.96%), Germany (n = 65, 7.28%), United Kingdom (n = 45, 5.04%), India (n = 45, 5.04%), Japan (n = 43, 4.82%), Italy (n = 37, 4.14%), South Korea (n = 34, 3.81%), and Canada (n = 25, 2.80%) (Table 1 and Figure 2).

FIGURE 2

Figure 2. Global analysis of the research trends in atrial myxoma based on the origin of the publications.

TABLE 1

Table 1. Top 10 countries/regions by publications and citations.

The highest number of total citations were from the USA (2,392), followed by Germany (n = 1,084), China (n = 1,027), United Kingdom (n = 750), Italy (n = 497), Turkey (n = 482), Japan (n = 379), Canada (n = 373), Switzerland (n = 353), and India (n = 329) (Table 1). Therefore, these countries were shown to be interested in atrial myxoma-related research. VOSviewer was used to analyze the co-operation between different countries. The line between nodes indicates co-authorship between countries; the thicker the line, the stronger the co-operative relationship. The results showed that the USA, China, and Turkey had the highest levels of co-operation with other countries; however, co-operation between the other countries showed a weak relationship (Figure 3).

FIGURE 3

Figure 3. Co-occurrence map of countries/regions. The size of the nodes represents the number of articles; the thickness of the curve represents the strength of the collaboration; the colors represent different collaboration groups.

3.3. Analysis of distribution and co-operation of leading institutions

A total of 23 institutions were involved in publishing atrial myxoma-related papers. The top five institutions with the highest number of publications were the Mayo Clinic (n = 15), Fujian Medical University (n = 13), Zhejiang University (n = 9), All India Institute of Medical Sciences (n = 9), and Sichuan University (n = 8) (Table 2).

TABLE 2

Table 2. Top 10 institutions by publications and citations.

The top five institutions with the highest number of total citations were the Mayo Clinic (n = 474), Washington University (n = 170), University of Chicago (n = 167), University Hospitals Leuven (n = 152), and Yokohama City University (n = 149) (Table 2). A co-operation network has been formed among various institutions; however, the co-operation is relatively decentralized and limited, without close co-operation. Most institutions with a high volume of publications and high number of citations are from the USA and China, thus, research in other countries needs to be improved. The phenomenon of a high number of papers issued by institutions in the USA and China may be related to the incidence rate and more scientific research funding (Figure 4).

FIGURE 4

Figure 4. Co-occurrence map of institutions. The size of the nodes represents the number of articles; the thickness of the curve represents the strength of the collaboration; the colors represent different collaboration groups.

3.4. Analysis of authors and co-cited authors

The author co-occurrence analysis identified the core authors in the atrial myxoma-related research field and the strength of collaboration between authors. Regarding the co-cited analysis, when two authors or papers are cited by a third author or paper at the same time, the two authors or papers have a co-cited relationship. Among the authors, Yuan SM (n = 12), Schaff HV (n = 4), Reardon M (n = 3), Gao C (n = 3), Wang G (n = 3), Agaimy A (n = 3), and Strecker T (n = 3) had the highest number of publications (Table 3 and Figure 5A). Yuan SM, the author with the highest number of articles, has performed in depth studies on atrial myxoma; however, the author is relatively isolated and has little co-operation with other authors. A co-operation network has been formed among scholars, but it is relatively decentralized (Figure 5A). The closer the color of the nodes are to yellow in Figure 5B, the more authors are cited. The citation analysis showed that Schaff HV (n = 241), Lang R (n = 167), Sugeng I (n = 167), Connolly H (n = 147), and Yuan SM (n = 127) had the most citations. Schaff HV is active and influential in this research field (Table 3, Figures 5B,C). The co-citation analysis showed that Reynen K (n = 312), Pinede I (n = 195), Carney J (n = 129), Burke A (n = 92), and Stratakis C (n = 92) had the most co-citations (Table 3 and Figure 5D).

FIGURE 5

Figure 5. (A) Co-occurrence map of authors. The size of the nodes represents the number of articles. (B) Superimposition map of cited authors. The size of the nodes represents the number of articles. (C) Cited authors analysis map. The size of the nodes represents the number of citations. (D) Co-cited authors analysis map. The size of the nodes represents the number of co-citations.

TABLE 3

Table 3. Top 10 authors and co-cited authors.

3.5. Analysis of keyword co-occurrence, clustering, and burst terms

Through keyword co-occurrence and prominence analysis, we can identify the changing trend of research topics over time. A total of 122 keywords were obtained; the top 10 keywords were cardiac myxoma (n = 268), myxoma (n = 261), tumor (n = 153), experience (n = 122), left atrial-myxoma (n = 104), atrial-myxoma (n = 104), diagnosis (n = 103), atrial myxoma (n = 100), echocardiography (n = 91), and heart (n = 84) (Figures 6, 7). By rerunning the software, selecting the pathfinder in the clipping mode, and using the logarithmic likelihood algorithm (LLR) to extract the nominal terms from the keywords in the cited literature to name the clusters, a total of 17 clustering words were obtained as follows: #0 heart atria, #1 atrial myxoma, #2 cardiac myxoma, #3 papillary fibroelastoma, #4 intracranial aneurysm, #5 complication, #6 transesophageal echocardiography, #7 cardiac tumors, #8 mitral valve, #9 primary cardiac tumor, #10 Carney complex, #11 minimal access, #12 right atrium, #13 Epstein–Barr virus, #14 artery, #15 actin isoforms, #16 volume (Figure 8). In addition, a total of 20 keyword-highlighted analysis results were obtained. From 2008 to 2012, the highlighted keywords were surgical treatment, experience, heart atria, papillary fibroelastoma, magnetic resonance imaging, disease, and cardiopulmonary bypass. From 2013 to 2017, the highlighted keywords were management, surgery, follow-up, pulmonary embolism, stroke, expression, and cardiac surgical procedure. Furthermore, from 2018 to 2022, the highlighted keywords were case report, resection, risk factor, patient, excision, patent foramen ovale (Figure 9).

FIGURE 6

Figure 6. Keyword co-occurrence analysis map obtained using VOSviewer. The size of the nodes represents the number of occurrences; the thickness of the curve represents the strength of collaboration; the different colors represent the different clusters.

FIGURE 7

Figure 7. Keyword density visualization analysis. The higher the intensity of the red color node, the higher the number of keywords.

FIGURE 8

Figure 8. Keyword clustering map analysis through CiteSpace. A total of 17 categories of keywords were obtained. The different color blocks represent different keyword clusters.

FIGURE 9

Figure 9. Keywords burst analysis by CiteSpace.

3.6. Analysis of leading journals and co-cited journals

The top five high-yield journals were the Journal of Cardiac Surgery (n = 27), Texas Heart Institute Journal (n = 27), Heart Surgery Forum (n = 22), Echocardiography—A Journal of Cardiovascular Ultrasound and Allied Techniques (n = 22), Journal of Cardiothoracic Surgery (n = 21), and the Journal of Cardiothoracic and Vascular Anesthesia (n = 21). The most cited journals were Annals of Thoracic Surgery (n = 284), Journal of Cardiac Surgery (n = 243), Texas Heart Institute Journal (n = 238), Journal of Cardiothoracic Surgery (n = 199), and the International Journal of Cardiology (n = 190). The division of cited journals is mostly Q4, which indicates that the overall level of research on atrial myxoma require further improvement (Table 4).

TABLE 4

Table 4. Top 10 journals by publications and citations.

Analysis of the co-cited journals showed that 113 journals were co-cited. The top five co-cited journals were Annals of Thoracic Surgery (n = 1,067), Journal of Thoracic and Cardiovascular Surgery (n = 517), New England Journal of Medicine (n = 454), American Journal of Cardiology (n = 414), and Circulation (n = 409) (Table 5 and Figure 10).

FIGURE 10

Figure 10. Co-cited journals analysis map. The size of the nodes represents the number of co-citations.

TABLE 5

Table 5. Top 10 co-cited journals.

3.7. Analysis of reference co-occurrence and burst references

A total of 82 references were obtained. The top 10 cited references were Simpson L (2008), Uzun O (2007), Kirkpatrick J (2004), Lee VH (2007), Hoffmeier A (2014), Veugelers K (2004), Shanmugam G (2006), Gulati S (2004), Ekinci E (2004), and Loong F (2010) (Table 6).

TABLE 6

Table 6. Top 10 references by citations.

In addition, a total of 10 references had the strongest citation bursts. From 2004 to 2007, the highlighted references were Pinede L (2001), Grenbenc ML (2002), Keeling IM (2002), and Shapiro LM (2001). From 2009 to 2012, the highlighted references were Lee VH (2007) and Swartz MF (2006). From 2013 to 2017, the highlighted references were Garatti A (2012), Lee SJ (2012), Hoffmeier A (2014), and Shah IK (2014) (Figure 11).

FIGURE 11

Figure 11. References burst analysis by CiteSpace.

4. Discussion

Using the CiteSpace and VOSviewer software, this study conducted an in-depth analysis of the research status of atrial myxoma and summarized the knowledge base and current research hotspots of atrial myxoma. This bibliometric analysis revealed that the main research topics and hotspots in atrial myxoma included surgical methods, case reports, genetic and molecular studies. The results provide reference for future research on atrial myxoma and identify the potential direction of exploration.

4.1. Scientific co-operation among countries, institutions, and authors

In the national co-operation relationship map (Figure 2), the USA has the largest node diameter, followed by China, Turkey, Germany, United Kingdom, and India. The total number of papers issued by the above six countries was 557, accounting for 62% of the total number of papers issued by all countries. This indicates that the above countries have formed a strong co-operation network and have made great contributions to the atrial myxoma research field. The number of studies and depth of research by American scholars far exceed those in other countries.

From the perspective of co-operation between authors and institutions, as shown in Figure 4, a total of 23 scientific research institutions have studied atrial myxoma from different aspects, forming a co-operation network centered on the MayoClinic, Fujian Medical University, Zhejiang University, All India Institute of Medical Sciences, and Sichuan University. These five institutions have issued 54 papers, accounting for 6% of the total number of papers issued by all institutions. Fujian Medical University, All India Institute of Medical Sciences, and Sichuan University have conducted in-depth research; however, they are relatively isolated and have little co-operation with other institutions. The number of papers issued by the MayoClinic (n = 15) is higher than that of other institutions, accounting for 28% of papers issued by the above institutions. Its research focuses on surgical methods for atrial myxoma resection (22), neuroimaging (23), multimodal imaging, and 3D printing for the evaluation of tumor morphology (24, 25).

4.2. Co-citation among authors, journals, and cited documents

In the co-citation analysis of authors (Figure 5D), Reynenk K, Pinede L, Carney JA, Burke AP, and Stratakis CA are the top five authors regarding the number of cited authors, all of whom are foreign authors.

Among tumors with unknown biological behavior, Reynenk K was cited 312 times, indicating that his research contents had a high influence. The co-citation map of journals (Figure 10) shows that manuscript in Annals in Thoracic Surgery were cited most frequently, up to 1,067 times, indicating that manuscripts represented by Annals in Thoracic Surgery are the main source of literature research in the field of atrial myxoma. The literature with the highest citation rate is “Reynen K. Cardiac Myxomas. New England Journal of Medicine, 1995”, a review of cardiac myxomas, which summarizes the basic knowledge of cardiac myxomas from epidemiology, pathology, clinical manifestations, physical examination, diagnostic testing, differential diagnosis, treatment, etc. Although cardiac myxoma is histologically benign, it may have fatal effects due to its location. Different symptoms depend on the size, activity, and location of the tumor. Echocardiography, including the transesophageal approach, is the most important diagnostic tool; computed tomography (CT) and magnetic resonance imaging (MRI) may also be helpful. The tumor should be resected as soon as possible, which is associated with a good long-term prognosis and rare recurrence rate. In the follow-up examination, echocardiography is essential.

4.3. Research hotspots, trends, and prospects for atrial myxoma

4.3.1. Research hotspots

Keywords are the central argument of a document; they reflect the core content of the document. Through keyword analysis, we can judge the research hotspots of atrial myxoma and determine the correct research direction. The keyword co-occurrence analysis map (Figure 6) has a large diameter, and the top keywords were as follows: cardiac myxoma, myxoma, tumor, experience, left atrial-myxoma, atrial-myxoma, diagnosis, atrial myxoma, echocardiography, heart, management, cardiac tumor, embolism, stroke, manifestation, and resection. The high frequency keywords in the above literature are closely related to the diagnosis and treatment of atrial myxoma and its complications. Cardiac myxoma is the most common primary benign cardiac tumor (accounting for 50% of primary cardiac tumors). The application of modern imaging technology in clinical practice, especially two-dimensional echocardiography, CT, and MRI, is helpful in the timely diagnosis of myxoma. However, the lack of specific clinical features, insufficient understanding of the disease, and rare prevalence may lead to misdiagnoses (26). Early diagnosis and treatment of atrial myxoma is very important to prevent embolism. The irregular surface of myxoma appears to be related to the embolic event (27).

Emergency physicians should evaluate the source of emboli when considering cerebrovascular accidents in patients under 35 years of age. A 28-year-old male with no medical history went to the emergency department for treatment because he began to develop acute left hemiplegia and facial ptosis on the day before arrival. Brain CT revealed focal ischemia; therefore, the emergency doctor performed bedside ultrasound and found a large, movable left atrial mass. After admission and confirmation of imaging, the mass was removed surgically. In otherwise healthy young people, a heart mass should be considered as the cause of unexplained stroke-like symptoms (28). It is reported that as many as 40% of patients with left atrial myxoma have systemic embolism, and half of them have brain involvement. The clinicopathological features of intracerebral embolism in left atrial myxoma and its association with the progressive implantation of tumor emboli and the potential pathogenic effects of interleukin-6 and matric metalloproteinases have been reviewed previously (29).

The keyword clustering map (Figure 8) revealed that #1 atrial myxoma, #2 cardiac myxoma, #3 papillary fibroelastoma, #7 cardiac tumors, and #9 primary cardiac tumors are related to tumor types. Some researchers have proposed a hypothesis regarding the origin of cardiac myxoma, which includes evaluating the significance of the atrial septal vascular tangle in the development of cardiac myxoma. Cardiac myxoma is thought to originate from pluripotent cardiac stem cells, which are often attached to the left side of the atrial septum. One of the characteristics of the attachment site is the aggregation of thick-walled vessels, which has been observed before the development of myxoma (30). A previous study compared the histology of a normal atrial septum and a septal flap resected with myxoma to evaluate the significance of the “vascular tangle” in the tumorigenesis of atrial myxoma. Based on the research results, a two-step hypothesis was proposed: the first step was to stimulate pluripotent cells to differentiate into endothelium and smooth muscle cells in the process of angiogenesis, and the subsequent step was the production of rich mucopolysaccharides that separated the smooth muscle cells, which would explain the rings, bands, or nests of myxoma cells around the endothelial lining space (31).

Regarding the keyword “intracranial aneurysm”, an analysis conducted by Yuan SM et al. revealed the advantages of multiple fusiform aneurysms of the middle cerebral artery associated with cardiac myxomas. Brain aneurysms occurred 53 months after cardiac myxoma resection. Left atrial myxomas are the most common cause of cerebral aneurysms. Removal of cardiac myxoma cannot avoid the occurrence of cerebral aneurysms; therefore, brain imaging monitoring is recommended even after cardiac myxoma resection (32). The neuroimaging manifestations of intracranial lesions related to myxoma vary, including multiple cerebral infarctions, aneurysm formation, intracranial focal hemorrhage, and space occupying lesions. Assessing the long-term progress in patients within 2 years of primary tumor resection requires regular MRI and CT angiography/magnetic resonance angiography/digital subtraction angiography. Furthermore, stable and effective chemotherapy drugs are urgently needed (33).

Regarding the keyword “complications”, myxoma can cause embolism, obstruction, and heart failure; however, it rarely causes chylothorax. Liao Z et al. reported a case of chylothorax caused by left atrial myxoma, which responded to diuretic treatment and was subsequently cured by resection of the cardiac myxoma (34). An article on the characteristics of ischemic stroke complications of cardiac myxoma patients in a single institution in Eastern China reviewed the medical records of 160 cardiac myxoma patients from January 2006 to December 2019. They were divided into a stroke group or non-stroke group. The study identified the three most common neurological symptoms (hypoesthesia, hemiplegia, and facial paralysis), and that involvement of the middle cerebral artery and multiple lesions are clear signs of stroke in cardiac myxoma patients. Surgical resection is a relatively safe operation for the treatment of both stroke and non-stroke patients (35).

“Transesophageal echocardiography” (TEE) can usually provide sufficient information for surgical resection. TEE with high sensitivity provides an excellent morphological definition that is helpful for diagnosis and follow-up (36, 37). TEE is important and practical for patients undergoing intracardiac mass resection during the perioperative period, and is helpful for monitoring and guidance during the surgical process (38, 39).

“Carney syndrome” can be divided into sporadic and familial; it is a rare autosomal dominant genetic disease and the most common familial cardiac myxoma. Most patients have an inactivation mutation of PRKAR1A on chromosome 17q22-24. Patients with Carney syndrome may have general symptoms of cardiac myxoma, such as fatigue, fever, body mass decline, myalgia, arthralgia, etc. In addition, they may also have skin lesions, lentigo, skin myxoma, and other characteristic skin manifestations, as well as multiple adenomas in the whole body (40, 41). If cardiac myxomas occur frequently at a relatively young age, the possibility of Carney syndrome should be considered (42).

“Minimal access” is associated with the development of surgical methods for myxoma removal. The “Epstein–Barr virus” (EBV) and “actin isoforms” are associated with the pathology of atrial myxoma. Jantuan E et al. suggested that cardiac myxoma can upregulate autophagy and create a favorable environment for EBV-driven tumorigenesis. This study is the first to describe the expression of autophagy-related genes and proteins in the tumor microenvironment in cardiac myxoma. The microenvironment of cardiac myxoma is dynamic; there are many cell types and different molecular pathways at work (43). Surgical resection of cardiac myxoma is still the main treatment method to avoid systemic or pulmonary embolism and harmful complications. However, recurrence is not uncommon and may be related to incomplete surgical resection (e.g., leaving some myxoma cells in the atrial septum) and/or that only some specific genetic characteristics are known (e.g., Carney complex). In the near future, the proposed miRNA-based therapy may play a key role in avoiding recurrence. Although the pathological groundbreaking research is promising, further research is still needed to understand how miRNA signal transduction directly regulates the pathophysiology of cardiac tumors. Further research should aim to investigate the causal relationship between different miRNAs and cell overgrowth, considering myxoma and other histological types of cardiac tumors. Thus, miRNA-based treatment of cardiac myxoma is a new potential therapeutic application (18).

The keywords burst analysis (Figure 9) shows the transfer of research hotspots in different periods and judges the potential development trend and frontier research. From 2008 to 2012, while focusing on disease diagnosis, surgical resection, as the most effective method to treat atrial myxoma (44), was a research hotspot. From 2013 to 2017, we gradually paid more attention to the role of follow-up (45) on patients after surgery. For patients with atrial myxoma, long-term follow-up should be carried out even after complete surgical resection, especially for patients with central nervous system manifestations before resection of atrial myxoma. In addition, complications such as embolism and stroke have become the focus of attention, and surgical treatment remains a high concern.

From 2018 to 2022, medical reports have attracted more and more attention and have become a hotspot. In addition, the risk factors of embolism in atrial myxoma patients has been gained increasing research attention. NYHA class (I/II), hypertension, irregular tumor surface, atypical tumor location, tumor basal stenosis, and elevated fibrinogen are important risk factors for embolism in cardiac myxoma patients; for such patients, early surgery may help to prevent embolism (46). Atrial fibrillation, irregular tumor surface, increased tumor size, and increased left atrial diameter were associated with an increased risk of embolism in patients with left atrial myxoma. Due to the increased possibility of embolism, early surgery should be arranged for such patients (47).

The surgical treatment of cardiac myxoma is also constantly improving. Structural cardiac abnormalities, such as atrial myxoma and patent foramen ovale, may play a role in brain injury. Because they can lead to abnormal cerebral embolism and cardiomyopathy, they may be related to sudden cardiogenic embolism events, and are increasingly valued (48).

In recent years, increasing attention has been paid to case reports, which promote our understanding of atrial myxoma in many ways. Kynta R reported a patient with chronic liver disease; a subsequent investigation found that there were masses in his right atrium and ventricle, which were consistent with heart tumors. During the operation, a huge mass was removed from the right atrium. The tumor stem originated from the tympanic pharyngeal flap. The histological results are consistent with myxoma. This is a case of Budd–Chiari syndrome caused by right atrial myxoma, which is extremely rare (49). Ertürk T et al. reported a case of giant left atrial myxoma with cough syncope syndrome (50). Cardiac myxoma mainly originating from the left atrium is the most common type of benign cardiac tumor, whereas biatrial myxoma is extremely rare. Fan C et al. reported a rare case of exertional dyspnea and intermittent chest discomfort in a 55-year-old man due to a huge bilateral atrial mass with atrial fibrillation and hepatic hemangioma (51).

Baugh et al. described a rare case of a 62-year-old male with incidental fibroin associated diffuse large B-cell lymphoma (FA-DLBCL) and atrial myxoma. The general immunophenotypical characteristics of the entity are an activated B cell phenotype and EBV-positive; however, this case was a germinal center B cell phenotype and EBV-negative. The article suggests expanding the definition of FA-DLBCL to include EBV-negative cases (52). The most common neurological complication associated with atrial myxoma is cerebral infarction caused by embolism. Early complete resection of giant cardiac myxoma is the key to the treatment and prevention of stroke recurrence. Chang W et al. reported a successful case in which thrombolysis and arterial embolus removal were used as bridging therapy for early complete resection of giant cardiac myxoma for stroke treatment and prevention of recurrence (53). A 63-year-old man was admitted to hospital due to acute left heart failure after doing farm work. Bedside echocardiography found a huge left atrial myxoma and he rapidly developed into refractory cardiogenic shock. Extracorporeal membrane oxygenation (ECMO) of venous arteries and veins was immediately performed and the patient was transferred for further surgery, with good results. Therefore, it is recommended to conduct echocardiographic evaluation and surgical resection of myxoma in a timely manner. ECMO can serve as a bridge between metastasis and the perioperative period (54). Ma S et al. reported a case of missed diagnosis of right atrial myxoma; digestive symptoms, systemic symptoms, and immune system disorders occurred, leading to tricuspid valve obstruction. This case reported the critical result of a missed diagnosis of right atrial myxoma, and indicated the importance of systematic examination of patients. In addition, it calls for early diagnosis of cardiac myxoma and consideration of drug targets to inhibit the development of cardiac myxoma (55).

Surgical treatment of atrial myxoma is being increasingly abundant and includes right chest minimally invasive small incision surgery, thoracoscopic surgery, robot surgery, etc. (12–16). With the continuous development and improvement of new instruments and technologies, the surgical treatment of atrial myxoma can be improved further. With the application of rapid rehabilitation surgery in cardiac surgery, cardiac myxoma resection is expected to enter the field of daytime surgery, and the technology in minimally invasive cardiac surgery will have a broader application prospect.

4.3.2. Trends and prospects

In addition to the basic knowledge about the research topic, we also generalized the research hotspots in the past years and speculated frontiers in the near future. In the first frontier, surgical methods, the research gap is to explore safe, convenient, efficient and rapidly popularized surgical methods combined with new instruments and technologies. As for the second frontier, case report, the research gap is to provide more case reports, widely accumulate experience, and explore summaries from individual cases to commonalities. As for the third frontier, genetic and molecular studies, The research gap is to understand myxoma at the genetic and molecular levels, clarify its pathogenesis, and develop targeted drugs. These research gaps can guide future researchers to decipher the puzzles and improve their cooperation. Health policies can be supplemented in the future.

4.4. Limitations

There are still some limitations to our study: (1) Recently published articles may have low citations due to the limited time available for citations, and thus the study may be prone to research bias. (2) This study only included articles and reviews published in English, which may have overlooked some of the literature. (3) Only the citations and abstracts of the literature were analyzed and may have missed some essential information in the main text.

4.5. Future directions

Regarding the limitations mentioned above, our future research should: (1) With the rapid development of big data, this study may have a short timeframe and needs to be updated regularly. (2) The possible minor subtopics of atrial myxoma should be classified for more detailed statistical analysis. (3) When bibliometrics technology becomes more advanced, non-English sources will also be included in the study to obtain more comprehensive and accurate results.

5. Conclusions

In this study, CiteSpace software was used to analyze the research literature in the field of atrial myxoma over the past 20 years. This bibliometric analysis revealed that the main research topics and hotspots in atrial myxoma included surgical methods, case reports, genetic and molecular studies.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Author contributions

AG and JW designed the study. AG, JY, TT, YW and XS conducted the literature search. AG, NQ and NT analyzed the data and wrote the paper. JW and XW approved the final manuscript. All authors contributed to the article and approved the submitted version.

Funding

Wi Jieping Medical Foundation (320.6750.2022-25-1); China Postdoctoral Innovative Talent Support Program (BX20220047); The Fellowship of China Postdoctoral Science Foundation (2022M720528); Young Talent Support Project of Beijing Association of Science and Technology (BYESS2022182); Young Talent Support Project of Chinese Association of Chinese Medicine (CACM-2021-QNRC2-B04).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Burke A, Tavora F. The 2015 WHO classification of tumors of the heart and pericardium. J Thorac Oncol. (2016) 11(4):441–52. doi: 10.1016/j.jtho.2015.11.009

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Ceresa F, Calarco G, Franzì E, Patanè F. Right atrial lipoma in patient with cowden syndrome. Interact Cardiovasc Thorac Surg. (2010) 11(6):803–4. doi: 10.1510/icvts.2010.245001

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Ceresa F, Sansone F, Rinaldi M, Patanè F. Left atrial paraganglioma: diagnosis and surgical management. Interact Cardiovasc Thorac Surg. (2010) 10(6):1047–8. doi: 10.1510/icvts.2009.231043

PubMed Abstract | CrossRef Full Text | Google Scholar

4. MacGowan SW, Sidhu P, Aherne T, Luke D, Wood AE, Neligan MC, et al. Atrial myxoma: national incidence, diagnosis and surgical management. Ir J Med Sci. (1993) 162(6):223–6. doi: 10.1007/BF02945200

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Kunioka S, Fujita K, Iwasa S, Murakami H, Kamiya H, Yamazaki K, et al. A rare form of cardiac myxoma: interatrial septum tumor. J Surg Case Rep. (2020) 2020(9):rjaa333. doi: 10.1093/jscr/rjaa333

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Kearney A, Corry N, Menown IBA. Massive left atrial myxoma presenting with troponin-positive chest pain. Cardiol Ther. (2020) 9(2):577–80. doi: 10.1007/s40119-020-00187-2

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Yoon DH, Roberts W. Sex distribution in cardiac myxomas. Am J Cardiol. (2002) 90(5):563–5. doi: 10.1016/s0002-9149(02)02540-7

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Keeling IM, Oberwalder P, Anelli-Monti M, Schuchlenz H, Demel U, Tilz GP, et al. Cardiac myxomas: 24 years of experience in 49 patients. Eur J Cardiothorac Surg. (2002) 22(6):971–7. doi: 10.1016/s1010-7940(02)00592-4

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Orlandi A, Ciucci A, Ferlosio A, Genta R, Spagnoli LG, Gabbiani G. Cardiac myxoma cells exhibit embryonic endocardial stem cell features. J Pathol. (2006) 209(2):231–9. doi: 10.1002/path.1959

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Kuyama N, Hamatani Y, Fukushima S, Ikeda Y, Nakai E, Okada A, et al. Left ventricular myxoma with carney complex. ESC Heart Fail. (2018) 5(4):713–5. doi: 10.1002/ehf2.12282

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Shrestha S, Raut A, Jayswal A, Yadav RS, Poudel CM. Atrial myxoma with cerebellar signs: a case report. J Med Case Rep. (2020) 14(1):29. doi: 10.1186/s13256-020-2356-5

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Kadiroğulları E, Onan B, Aydın Ü, Başgöze S, Şen O. A comparison of robotically-assisted endoscopic versus sternotomy approach for myxoma excision: a single-center experience. Turk Gogus Kalp Damar Cerrahisi Derg. (2020) 28(3):450–9. doi: 10.5606/tgkdc.dergisi.2020.19278

CrossRef Full Text | Google Scholar

13. Ko PJ, Chang CH, Lin PJ, Chu JJ, Tsai FC, Hsueh C, et al. Video-assisted minimal access in excision of left atrial myxoma. Ann Thorac Surg. (1998) 66(4):1301–5. doi: 10.1016/s0003-4975(98)00759-0

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Santana O, Reyna J, Grana R, Buendia M, Lamas GA, Lamelas J. Outcomes of minimally invasive valve surgery versus standard sternotomy in obese patients undergoing isolated valve surgery. Ann Thorac Surg. (2011) 91(2):406–10. doi: 10.1016/j.athoracsur.2010.09.039

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Shi J, Wang Y, Wang Q, Bing X, Ma Z. Simultaneously performed, totally endoscopic left atrial myxoma resection and lobectomy. Heart Surg Forum. (2020) 23(3):E292–4. doi: 10.1532/hsf.2839

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Doulamis IP, Spartalis E, Machairas N, Schizas D, Patsouras D, Spartalis M, et al. The role of robotics in cardiac surgery: a systematic review. J Robot Surg. (2019) 13(1):41–52. doi: 10.1007/s11701-018-0875-5

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Cheng N, Wu Y, Zhang H, Guo Y, Cui H, Wei S, et al. Identify the critical protein-coding genes and long noncoding RNAs in cardiac myxoma. J Cell Biochem. (2019) 120(8):13441–52. doi: 10.1002/jcb.28618

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Nenna A, Loreni F, Giacinto O, Chello C, Nappi P, Chello M, et al. miRNAs in cardiac myxoma: new pathologic findings for potential therapeutic opportunities. Int J Mol Sci. (2022) 23(6):3309. doi: 10.3390/ijms23063309

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Zhu S, Li L, Gu Z, Chen C, Zhao Y. 15 years of small: research trends in nanosafety. Small. (2020) 16(36):e2000980. doi: 10.1002/smll.202000980

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Chen C. Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci U S A. (2004) 101 (Suppl 1):5303–10. doi: 10.1073/pnas.0307513100

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Ma D, Guan B, Song L, Liu Q, Fan Y, Zhao L, et al. A bibliometric analysis of exosomes in cardiovascular diseases from 2001 to 2021. Front Cardiovasc Med. (2021) 8:734514. doi: 10.3389/fcvm.2021.734514

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Konecny T, Reeder G, Noseworthy PA, Konecny D, Carney JA, Asirvatham SJ. Percutaneous ablation and retrieval of a right atrial myxoma. Heart Lung Circ. (2014) 23(11):e244–7. doi: 10.1016/j.hlc.2014.07.059

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Brinjikji W, Morris JM, Brown RD, Thielen KR, Wald JT, Giannini C, et al. Neuroimaging findings in cardiac myxoma patients: a single-center case series of 47 patients. Cerebrovasc Dis. (2015) 40(1–2):35–44. doi: 10.1159/000381833

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Ali M, Pham AN, Pooley RA, Rojas CA, Mergo PJ, Pham SM. Three-dimensional printing facilitates surgical planning for resection of an atypical cardiac myxoma. J Card Surg. (2020) 35(10):2863–5. doi: 10.1111/jocs.14896

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Saef J, Jellis C, Unai S, Tan C, Dresing T, Ayoub C. Multimodality imaging evaluation of incidentally discovered intracardiac mass. Echocardiography. (2022) 39(6):837–40. doi: 10.1111/echo.15354

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Fomin VV, Kogan EA, Morozova NS, Chichkova NV, Komarov RN, Kurasov NO, et al. Cardiac myxoma: challenge in diagnostics. Case report. Ter Arkh. (2021) 93(4):470–7. doi: 10.26442/00403660.2021.4.200685

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Wen XY, Chen YM, Yu LL, Wang SR, Zheng HB, Chen ZB, et al. Neurological manifestationes of atrial myxoma: a retrospective analysis. Oncol Lett. (2018) 16(4):4635–9. doi: 10.3892/ol.2018.9218

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Bradshaw JC, Arthur J, Lewis ZB. Ultrasound-assisted diagnosis of embolic cerebrovascular accident from left atrial myxoma in the emergency department. J Emerg Med. (2021) 61(4):e60–3. doi: 10.1016/j.jemermed.2021.05.010

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Aguilar C, Carbajal T, Beltran BE, Segura P, Muhammad S, Choque-Velasquez J. Cerebral embolization associated with parenchymal seeding of the left atrial myxoma: potential role of interleukin-6 and matrix metalloproteinases. Neuropathology. (2021) 41(1):49–57. doi: 10.1111/neup.12697

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Dübel HP, Knebel F, Gliech V, Konertz W, Rutsch W, Baumann G, et al. Atypical vessels as an early sign of intracardiac myxoma? Cardiovasc Ultrasound. (2004) 2:13. doi: 10.1186/1476-7120-2-13

CrossRef Full Text | Google Scholar

31. Vaideeswar P, Yadav S. Vascular tangle in the inter-atrial septum—is it the source of cardiac myxoma? Indian J Pathol Microbiol. (2021) 64(3):469–71. doi: 10.4103/IJPM.IJPM_1215_20

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Yuan SM. Cerebral aneurysms due to cardiac myxoma. J Coll Physicians Surg Pak. (2019) 29(8):763–7. doi: 10.29271/jcpsp.2019.08.763

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Zhang S, Zhang Q, Yu H, Liu L, Sun R, Song X, et al. Neuroimaging characteristics and long-term prognosis of myxoma-related intracranial diseases. Neuroradiology. (2020) 62(3):307–17. doi: 10.1007/s00234-019-02314-w

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Liao Z, Huang W, Hu Q, Wang Z, Pan L, Zheng W. Chylothorax caused by left atrial myxoma: a rare case report. J Card Surg. (2021) 36(12):4792–5. doi: 10.1111/jocs.16074

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Zhang Y, Ye Z, Fu Y, Zhang Z, Ye Q, Chen F, et al. Characterizations of ischemic stroke complications in cardiac myxoma patients at a single institution in eastern China. Neuropsychiatr Dis Treat. (2021) 17:33–40. doi: 10.2147/NDT.S280641

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Meng Q, Lai H, Lima J, Tong W, Qian Y, Lai S. Echocardiographic and pathologic characteristics of primary cardiac tumors: a study of 149 cases. Int J Cardiol. (2002) 84(1):69–75. doi: 10.1016/s0167-5273(02)00136-5

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Oliveira R, Branco L, Galrinho A, Abreu A, Abreu J, Fiarresga A, et al. Cardiac myxoma: a 13-year experience in echocardiographic diagnosis. Rev Port Cardiol. (2010) 29(7–8):1087–100.21066964

PubMed Abstract | Google Scholar

38. Kumar US D, Wali M, Shetty SP, Sujay KR. Left atrial myxoma—a tumor in transit. Ann Card Anaesth. (2019) 22(4):432–4. doi: 10.4103/aca.ACA_232_18

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Munirathinam GK, Kumar B, Singh H. Role of transesophageal echocardiography in the recurrent biatrial myxoma of uncommon origin. Ann Card Anaesth. (2022) 25(1):85–8. doi: 10.4103/aca.ACA_71_20

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Yuan SM, Yan SL, Wu N. Unusual aspects of cardiac myxoma. Anatol J Cardiol. (2017) 17(3):241–7. doi: 10.14744/AnatolJCardiol.2017.7557

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Correa R, Salpea P, Stratakis CA. Carney complex: an update. Eur J Endocrinol. (2015) 173(4):M85–97. doi: 10.1530/EJE-15-0209

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Yokoyama S, Nagao K, Higashida A, Aoki M, Yamashita S, Fukuda N, et al. Diagnosis of carney complex following multiple recurrent cardiac myxomas. Gen Thorac Cardiovasc Surg. (2022) 70(1):87–91. doi: 10.1007/s11748-021-01719-w

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Jantuan E, Chiu B, Chiu B, Shen F, Oudit GY, Sergi C. The tumor microenvironment may trigger lymphoproliferation in cardiac myxoma. Transl Oncol. (2021) 14(1):100911. doi: 10.1016/j.tranon.2020.100911

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Kuroczyński W, Peivandi AA, Ewald P, Pruefer D, Heinemann M, Vahl CF. Cardiac myxomas: short- and long-term follow-up. Cardiol J. (2009) 16(5):447–54.

Google Scholar

45. Wan Y, Du H, Zhang L, Guo S, Xu L, Li Y, et al. Multiple cerebral metastases and metastatic aneurysms in patients with left atrial myxoma: a case report. BMC Neurol. (2019) 19(1):249. doi: 10.1186/s12883-019-1474-4

PubMed Abstract | CrossRef Full Text | Google Scholar

46. Liu Y, Wang J, Guo L, Ping L. Risk factors of embolism for the cardiac myxoma patients: a systematic review and metanalysis. BMC Cardiovasc Disord. (2020) 20(1):348. doi: 10.1186/s12872-020-01631-w

PubMed Abstract | CrossRef Full Text | Google Scholar

47. Kalçık M, Bayam E, Güner A, Küp A, Kalkan S, Yesin M, et al. Evaluation of the potential predictors of embolism in patients with left atrial myxoma. Echocardiography. (2019) 36(5):837–43. doi: 10.1111/echo.14331

CrossRef Full Text | Google Scholar

48. Kelley RE, Kelley BP. Heart-brain relationship in stroke. Biomedicines. (2021) 9(12):1835. doi: 10.3390/biomedicines9121835

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Kynta RL, Rawat S, Lyngdoh BS, Gunasekaran AK, Fanai V, Kapoor M, et al. Eustachian valve myxoma: a rare cause of budd-chiari syndrome. Gen Thorac Cardiovasc Surg. (2021) 69(8):1243–6. doi: 10.1007/s11748-021-01641-1

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Tekin E E. Giant left atrial myxoma presenting with cough-syncope syndrome. Heart Surg Forum. (2021) 24(4):E7090–712. doi: 10.1532/hsf.3991

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Fan C, Zhang H, Zhuang H, Jiang Z, Tan H, Iroegbu CD, et al. Case report: giant biatrial myxoma mimicking malignant cardiac tumor in a patient with a hepatic angiomatous mass. Front Cardiovasc Med. (2021) 8:676807. doi: 10.3389/fcvm.2021.676807

PubMed Abstract | CrossRef Full Text | Google Scholar

52. Baugh L, Brown N, Song JY, Pandya S, Montoya V, Fibrin-Associated PA. EBV-negative diffuse large B-cell lymphoma arising in atrial myxoma: expanding the Spectrum of the entity. Int J Surg Pathol. (2022) 30(1):39–45. doi: 10.1177/10668969211014959

PubMed Abstract | CrossRef Full Text | Google Scholar

53. Chang WS, Li N, Liu H, Yin JJ, Zhang HQ. Thrombolysis and embolectomy in treatment of acute stroke as a bridge to open-heart resection of giant cardiac myxoma: a case report. World J Clin Cases. (2021) 9(25):7572–8. doi: 10.12998/wjcc.v9.i25.7572

PubMed Abstract | CrossRef Full Text | Google Scholar

54. Tian L, Zhang S, Xu J, Han X. Extracorporeal membrane oxygenation as a bridge between transfer and perioperative periods in refractory cardiogenic shock secondary to a large left atrial myxoma. Heart Surg Forum. (2021) 24(2):E215–6. doi: 10.1532/hsf.3501

PubMed Abstract | CrossRef Full Text | Google Scholar

55. Ma S, Xu Q, Shi R, Zhang X, Chen X. The omitted symptoms challenge the diagnosis of right atrial myxoma: a case report. BMC Cardiovasc Disord. (2020) 20(1):149. doi: 10.1186/s12872-020-01413-4

PubMed Abstract | CrossRef Full Text | Google Scholar